Details
Stereochemistry | ACHIRAL |
Molecular Formula | C2H7NO3S |
Molecular Weight | 125.147 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NCCS(O)(=O)=O
InChI
InChIKey=XOAAWQZATWQOTB-UHFFFAOYSA-N
InChI=1S/C2H7NO3S/c3-1-2-7(4,5)6/h1-3H2,(H,4,5,6)
Molecular Formula | C2H7NO3S |
Molecular Weight | 125.147 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionSources: https://doi.org/10.1016/S0378-1097(03)00611-6Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 |
https://www.ncbi.nlm.nih.gov/pubmed/26208967
Sources: https://doi.org/10.1016/S0378-1097(03)00611-6
Curator's Comment: description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/3676193 | http://www.medscape.com/viewarticle/804080 | https://www.ncbi.nlm.nih.gov/pubmed/21334852 |
https://www.ncbi.nlm.nih.gov/pubmed/26208967
Taurine is a semi-essential amino acid and is not incorporated into proteins. Taurine is considered conditionally essential because it cannot be synthesized by infants younger than 4-6 weeks, and it may not be adequately synthesized in patients receiving long-term parenteral nutrition and patients with short-term hypermetabolic conditions. In mammalian tissues, taurine is ubiquitous and is the most abundant free amino acid in the heart, retina, skeletal muscle, brain, and leukocytes. Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg. Taurine is a component of energy drinks, with many contain 1000 mg per serving. In medicine, taurine supplementation demonstrated efficacy in relieving symptoms of heart failure, hepatitis, hypertension and psychotic disorder. Taurine exerts many physiological functions, including membrane stabilization, osmoregulation and cytoprotective effects, antioxidant and anti-inflammatory actions as well as modulation of intracellular calcium concentration and ion channel function. In addition taurine may control muscle metabolism and gene expression, through yet unclear mechanisms. The cellular and biochemical mechanisms mediating the actions of taurine are not fully known.
CNS Activity
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL1907607 Sources: https://www.ncbi.nlm.nih.gov/pubmed/23637894 |
|||
Target ID: CHEMBL3392921 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9279812 |
406.0 µM [EC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | TAURINE Approved UseTaking 2-3 grams of taurine by mouth one to two times daily for 6-8 weeks seems to improve heart function and symptoms in patients with moderate heart failure to severe heart failure. Some patients with severe heart failure rapidly improve from NYHA class IV to II after 4-8 weeks of treatment. Improvement seems to continue for as long as taurine treatment is continued, up to one year. |
|||
Palliative | TAURINE Approved UseTaking 1.5-4 grams of taurine daily for up to 3 months improves liver function in people with hepatitis. |
|||
Preventing | URSA Complex Approved UseTaurine is a component of energy drinks used for relieving of fatigue |
|||
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Calcium-mediated transductive systems and functionally active gap junctions in astrocyte-like GL15 cells. | 2001 |
|
Beneficial effects of an "energy drink" given to sleepy drivers. | 2001 |
|
The influence of a taurine containing drink on cardiac parameters before and after exercise measured by echocardiography. | 2001 |
|
Changes in plasma and urinary taurine and amino acids in runners immediately and 24h after a marathon. | 2001 |
|
Isolation and characterization of an alpha 2-type zebrafish glycine receptor subunit. | 2001 |
|
New developments in the pharmacotherapy of alcohol dependence. | 2001 |
|
Oxygen metabolites in immune- stimulated ion transport in rat colon: modulation by taurine. | 2001 |
|
Gene expression of the taurine transporter and taurine biosynthetic enzymes in rat kidney after antidiuresis and salt loading. | 2001 Apr |
|
Zinc and the eye. | 2001 Apr |
|
Increased taurine content in esophageal mucosa of children affected by gastroesophageal reflux. | 2001 Apr |
|
Conditioned nutritional deficiencies in the cardiomyopathic hamster heart. | 2001 Apr |
|
Dipolar coupling and ordering effects observed in magnetic resonance spectra of skeletal muscle. | 2001 Apr |
|
Killing of Schistosoma mansoni sporocysts by hemocytes from resistant Biomphalaria glabrata: role of reactive oxygen species. | 2001 Apr |
|
Cellular uptake of taurine by lactating porcine mammary tissue. | 2001 Apr |
|
Analysis of amino acids in human serum by isocratic reversed-phase high-performance liquid chromatography with electrochemical detection. | 2001 Apr 13 |
|
Fertilizability and developmental capacity of bovine oocytes cultured individually in a chemically defined maturation medium. | 2001 Apr 15 |
|
Endogenous glutamate-taurine interaction in striatum and nucleus accumbens of the freely moving rat: studies during the normal process of aging. | 2001 Apr 15 |
|
Reduction of phospholemman expression decreases osmosensitive taurine efflux in astrocytes. | 2001 Apr 23 |
|
Mast cell numbers in the young rat thalamus: a search for control factors. | 2001 Aug |
|
Taurine increases rat survival and reduces striatal damage caused by 3-nitropropionic acid. | 2001 Aug |
|
Osmolytes stabilize ribonuclease S by stabilizing its fragments S protein and S peptide to compact folding-competent states. | 2001 Aug 3 |
|
Effects of new taurine derivatives on primary immune response in rats. | 2001 Feb |
|
Effect of acamprosate and naltrexone, alone or in combination, on ethanol consumption. | 2001 Feb |
|
Taurine - monograph. | 2001 Feb |
|
Can this pill stop you from hitting the bottle? | 2001 Feb 12 |
|
Activation of an ATP-dependent K(+) conductance in Xenopus oocytes by expression of adenylate kinase cloned from renal proximal tubules. | 2001 Feb 9 |
|
The protective effect of taurine against thioacetamide hepatotoxicity of rats. | 2001 Jan |
|
Effects of methionine loading on plasma and erythrocyte sulphur amino acids and sulph-hydryls before and after co-factor supplementation in haemodialysis patients. | 2001 Jan |
|
Determination of bile acids in biological fluids by liquid chromatography-electrospray tandem mass spectrometry. | 2001 Jan |
|
Dietary taurine manipulations in aged male Fischer 344 rat tissue: taurine concentration, taurine biosynthesis, and oxidative markers. | 2001 Jul 1 |
|
Taurine modulates arginine vasopressin-mediated regulation of renal function. | 2001 Jun |
|
Enhanced fungicidal activity of N-chlorotaurine in nasal secretion. | 2001 Jun |
|
Occupational lead exposure and amino acid profiles and liver function tests in industrial workers. | 2001 Jun |
|
17 beta-estradiol protects neurons from ischemic damage and attenuates accumulation of extracellular excitatory amino acids. | 2001 Jun |
|
Swelling-activated taurine and K+ transport in human cervical cancer cells: association with cell cycle progression. | 2001 Mar |
|
Two-voxel localization sequence for in vivo two-dimensional homonuclear correlation spectroscopy. | 2001 Mar |
|
Reactive nitrogen oxygen species metabolize N-acetylbenzidine. | 2001 Mar |
|
Hypocholesterolemic effect of bile acid sulfonate analogs in hamsters. | 2001 Mar |
|
Effect of starvation on free histidine and amino acids in white muscle of milkfish Chanos chanos. | 2001 Mar |
|
Alteration of excitation-contraction coupling mechanism in extensor digitorum longus muscle fibres of dystrophic mdx mouse and potential efficacy of taurine. | 2001 Mar |
|
Relative reactivities of N-chloramines and hypochlorous acid with human plasma constituents. | 2001 Mar 1 |
|
Intrathecal magnesium sulfate attenuates algogenic behavior and spinal amino acids release after kainic acid receptor activation in rats. | 2001 Mar 30 |
|
Evaluation of urinary carnitine and taurine excretion in 5 cystinuric dogs with carnitine and taurine deficiency. | 2001 Mar-Apr |
|
Mechanisms of alcohol-nicotine interactions: alcoholics versus smokers. | 2001 May |
|
Pharmacological relapse prevention in alcohol dependence: from animal models to clinical trials. | 2001 May |
|
The influence of plasma on the disinfecting activity of the new antimicrobial agent N-chlorotaurine-sodium in comparison with chloramine T. | 2001 May |
|
N-chlorotaurine, a novel endogenous antimicrobial agent: tolerability testing in a mouse model. | 2001 May |
|
Characterization of the mouse bile salt export pump overexpressed in the baculovirus system. | 2001 May |
|
Identification of a novel form of renal glucosuria with overexcretion of arginine, carnosine, and taurine. | 2001 May |
|
Further studies on the effects of topical lactate on amino acid efflux from the ischemic rat cortex. | 2001 May 18 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3676193
Taurin occurs naturally in fish and meat. The mean daily intake from omnivore diets was determined to be around 58 mg.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9279812
Agonist properties of taurine on glycine receptor of supraoptic magnocellular neurones acutely dissociated from adult rats, using whole-cell voltage clamp. Responses to 1 mM taurine were blocked by strychnine but not by gabazine and showed no additivity with glycine-induced currents, indicating selective activation of glycine receptors.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 14:58:08 GMT 2023
by
admin
on
Fri Dec 15 14:58:08 GMT 2023
|
Record UNII |
1EQV5MLY3D
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Related Record | Type |
---|
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
LOINC |
26896-1
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
15208-2
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
56985-5
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
NCI_THESAURUS |
C45564
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
2981-9
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
15140-7
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
25985-3
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
20657-3
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
JECFA EVALUATION |
TAURINE
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
30563-1
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
17679-2
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
2979-3
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
NCI_THESAURUS |
C68442
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
DSLD |
2060 (Number of products:2643)
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
2980-1
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
13415-5
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
FDA ORPHAN DRUG |
298709
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
17678-4
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
44411-7
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
28595-7
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
27310-2
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
13814-9
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
25138-9
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
26614-8
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
2982-7
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
25533-1
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
15136-5
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
CFR |
21 CFR 573.980
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
DSLD |
504 (Number of products:17)
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
33214-8
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
32271-9
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
47782-8
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
||
|
LOINC |
9324-5
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
8167
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
DB01956
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
107-35-7
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
100000082407
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
203-483-8
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
1EQV5MLY3D
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
TAURINE
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
15891
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
10337
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | RxNorm | ||
|
1431306
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
DTXSID3021304
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
1EQV5MLY3D
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
CHEMBL239243
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
586
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
32428
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
507393
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
1123
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
SUB10836MIG
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
1643361
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
1424
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
4486
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
m10481
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | Merck Index | ||
|
C61962
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
6171
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY | |||
|
D013654
Created by
admin on Fri Dec 15 14:58:08 GMT 2023 , Edited by admin on Fri Dec 15 14:58:08 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
||
|
SALT/SOLVATE -> PARENT | |||
|
SUB_CONCEPT->SUBSTANCE | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> METABOLITE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |